阿帕替尼抗肿瘤治疗相关性高血压的观察

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Apatinib in the treatment of advanced malignant tumors and its effect on blood pressure.Methods Forty-two patients with advanced malignant tumors admitted to our hospital from January 1, 2016 to December 31, 2017 were enrolled in the study.They were divided into two groups according to random sampling, 21 cases each group.The control group received placebo and nutritional support treatment.The observation group was treated with Apatinib on the basis of the control group, and the total effective rate, adverse reactions,and grade of hypertension were observed and evaluated.Results The total effective rate of the observation group was higher than that of the control group (P＜0.05).The total incidence of adverse reactions in the observation group was higher than that in the control group, the difference was statistically significant (P＜0.05).The total incidence of hypertension in the observation group was higher than that in the control group, and the difference was statistically significant (P＜0.05).There was no significant difference in the grade of hypertension between the two groups (P＞0.05).Conclusion Apatinib has high clinical value in patients with advanced malignant tumors, which is beneficial to prolonging survival.However, the clinical incidence of hypertension is high, and the mechanism of blood pressure elevation needs further discussion.

Key words： Apatinib Advanced malignant tumor Survival Hypertension

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Jun
	XU Hai-ling
	HUA Min
	ZHOU Yuan-feng
	PING Xiang-hua

Cite this article:

ZHOU Jun,XU Hai-ling,HUA Min, et al. Observation on antineoplastic therapy-related hypertension with Apatinib[J]. 中国当代医药, 2020, 27(8): 66-68.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I8/66

[1]	张玥，俞静.阿帕替尼治疗晚期恶性肿瘤的临床疗效及安全性观察[J].临床和实验医学杂志，2018，17（9）：897-900.
[2]	崔海忠，戈伟，曹德东，等.甲磺酸阿帕替尼联合肝动脉栓塞化疗治疗中晚期原发性肝癌的效果[J].中国医药导报，2019，16（14）：88-91.
[3]	王学敏，张维红，杜伟娇，等.阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析[J].中国肺癌杂志，2017，20（11）：761-768.
[4]	詹志翔.阿帕替尼联合伊立替康和5-FU 治疗晚期胃癌的近期疗效和预后分析[J].中国实用医刊，2017，44（13）：39-42.
[5]	彭雨，李海涛，林大任，等.阿帕替尼治疗三线及三线以上晚期实体恶性肿瘤的临床疗效[J].包头医学院学报，2017，33（3）：8-9.
[6]	彭雨，李海涛，杨文丽，等.阿帕替尼在既往二线及二线以上治疗失败后的晚期肝细胞癌中的临床疗效分析[J].徐州医学院学报，2017，37（3）：178-181.
[7]	张伟，苏方，汪子书.阿帕替尼治疗乙型病毒性肝炎相关性晚期肝细胞癌的疗效观察[J].国际肿瘤学杂志，2019，46（1）：27-31.
[8]	王同彪，荣震，唐寒英，等.养阴清热法治疗甲磺酸阿帕替尼相关性高血压1例报道及体会[J].中医临床研究，2017，9（36）：15-16.
[9]	李玲，张芳文，南飞飞，等.阿帕替尼治疗难治性恶性肿瘤43例疗效观察[J].中华实用诊断与治疗杂志，2017，31（6）：594-596.
[10]	李杨，蔡林原.阿帕替尼治疗晚期恶性肿瘤患者的临床疗效及安全性观察[J].临床合理用药杂志，2019，12（2）：17-18.
[11]	杨宝玉，林小燕，王新利.阿帕替尼联合替吉奥治疗晚期胃癌效果观察[J].肿瘤研究与临床，2017，29（9）：630-633.
[12]	王茂勋，关露露，陈小兵.阿帕替尼治疗恶性肿瘤的现状和进展[J].肿瘤研究与临床，2018，30（4）：281-285.
[13]	刘丹，赵峻峰，史晓宇，等.新型抗血管生成药阿帕替尼在肿瘤治疗中的应用研究进展[J].河北北方学院学报（自然科学版），2017，33（10）：42-45.
[14]	朱志刚.阿帕替尼治疗晚期胃癌疗效与血压的相关性研究[J].中国药物与临床，2018，18（6）：85-86.
[15]	姜颖频，曹风军，杨冰冰，等.阿帕替尼治疗恶性肿瘤致继发性高血压的危险因素分析[J].湖北医药学院学报，2019，38（1）：49-52.